These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4956802)

  • 41. [Studies on pyrazine derivatives. XV. Synthesis and tuberculostatic effect of imidazoline pyrazines and imidazoline pyridines].
    Foks H; Janowiec M
    Acta Pol Pharm; 1982; 39(1-3):79-82. PubMed ID: 6817592
    [No Abstract]   [Full Text] [Related]  

  • 42. [Rifampicin sensitivity of mycobacteria].
    Daddi G; Lucchesi M; Mancini P; Matzeu M; Rossi P
    Ann Ist Carlo Forlanini; 1969; 29(1):17-28. PubMed ID: 4996680
    [No Abstract]   [Full Text] [Related]  

  • 43. [The sensitivity of Mycobacterium tuberculosis to rifampicin and its clinical effectiveness (author's transl)].
    Chen HL
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1980 Feb; 3(2):104-5. PubMed ID: 6774865
    [No Abstract]   [Full Text] [Related]  

  • 44. A comparison of the bactericidal activity of a series of rifampicins against Mycobacterium leprae.
    Pattyn SR
    Arzneimittelforschung; 1982; 32(1):15-7. PubMed ID: 7037013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Studies on the activity of the new antitubercular drugs: Pyrazinamide, rifomycin, 11.072 R. P].
    Manowska W
    Gruzlica; 1968 Apr; 36(4):387-8. PubMed ID: 4971135
    [No Abstract]   [Full Text] [Related]  

  • 46. Simultaneous identification of rifampin-resistant Mycobacterium tuberculosis and nontuberculous mycobacteria by polymerase chain reaction-single strand conformation polymorphism and sequence analysis of the RNA polymerase gene (rpoB).
    Kim BJ; Lee KH; Yun YJ; Park EM; Park YG; Bai GH; Cha CY; Kook YH
    J Microbiol Methods; 2004 Jul; 58(1):111-8. PubMed ID: 15177909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Detecting rpoB gene mutation in rifampin-resistant Mycobacterium tuberculosis by using the reverse dot-blot hybridization method].
    Wang W; Pan W; Jin W; Weng X; Yan R; Su B; Chen S; Zhang W; Lu H; Qi Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Oct; 25(10):591-4. PubMed ID: 12490124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New drugs for tuberculosis.
    Grassi C; Peona V
    Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Study of the biological characteristics of strains of M. tuberculosis resistant to isoniazid and rifampin].
    Diaconescu C; Iacob L
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1984; 33(2):151-62. PubMed ID: 6093222
    [No Abstract]   [Full Text] [Related]  

  • 50. Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates.
    Soudani A; Hadjfredj S; Zribi M; Masmoudi A; Messaoud T; Tiouri H; Fendri C
    J Clin Microbiol; 2007 Sep; 45(9):3095-7. PubMed ID: 17652484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibacterial activity of DL 473, a C3-substituted rifamycin derivative.
    Neu HC
    Antimicrob Agents Chemother; 1983 Sep; 24(3):457-60. PubMed ID: 6639006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The composition of rifamycin B and related rifamycins].
    Oppolzer W; Prelog V; Sensi P
    Experientia; 1964 Jun; 20(6):336-9. PubMed ID: 5855864
    [No Abstract]   [Full Text] [Related]  

  • 53. The x-ray analysis of the structure of rifamycin Y.
    Brufani M; Fedeli W; Giacomello G; Vaciago A
    Experientia; 1967 Jul; 23(7):508-12. PubMed ID: 6057726
    [No Abstract]   [Full Text] [Related]  

  • 54. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.
    Dabbs ER; Yazawa K; Mikami Y; Miyaji M; Morisaki N; Iwasaki S; Furihata K
    Antimicrob Agents Chemother; 1995 Apr; 39(4):1007-9. PubMed ID: 7785970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The evolving role of chemical synthesis in antibacterial drug discovery.
    Wright PM; Seiple IB; Myers AG
    Angew Chem Int Ed Engl; 2014 Aug; 53(34):8840-69. PubMed ID: 24990531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin.
    Staudinger T; Redl B; Glasgow BJ
    Biochim Biophys Acta; 2014 Apr; 1844(4):750-8. PubMed ID: 24530503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition by rifampin of African swine fever virus replication in tissue culture.
    Dardiri AH; Bachrach HL; Heller E
    Infect Immun; 1971 Jul; 4(1):34-6. PubMed ID: 5154875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Actions of the rifamycins.
    Wehrli W; Staehelin M
    Bacteriol Rev; 1971 Sep; 35(3):290-309. PubMed ID: 5001420
    [No Abstract]   [Full Text] [Related]  

  • 59. Desacetyl-rifamycins: preparation and antibacterial properties.
    Maggi N; Vigevani A; Pallanza R
    Experientia; 1968 Mar; 24(3):209-11. PubMed ID: 4969311
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of rifamycins and related antibiotics on the deoxyribonucleic acid-dependent ribonucleic acid polymerase of vaccinia virus particles.
    Szilágyi JF; Pennington TH
    J Virol; 1971 Aug; 8(2):133-41. PubMed ID: 4940241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.